Sign In
Buy ELVN
$59.42
-1.04 (-1.72%)
At Close: Aug 10, 2026
Imara Receives Orphan Drug Designation for IMR-687 for Treatment of Beta-thalassemia
11:00am, Wednesday, 24'th Jun 2020
IMARA Inc. (IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemogl
Here is What Hedge Funds Think About IMARA Inc. (IMRA)
05:57pm, Monday, 22'nd Jun 2020
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F
Here's Why We're Not Too Worried About IMARA's (NASDAQ:IMRA) Cash Burn Situation
12:44pm, Saturday, 13'th Jun 2020
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Imara reports promising data from mid-stage trial for sickle cell treatment
11:46am, Friday, 12'th Jun 2020
Imara Inc. announced positive interim results from a mid-stage clinical trial for its experimental sickle cell disease treatment. The Phase 2a study is testing IMR-687, an oral treatment, in adult pa
Imara Inc. (IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemogl
Imara to Present Data on IMR-687 in Sickle Cell Disease at the 25th Annual European Hematology Association (EHA) Congress
11:00am, Thursday, 21'st May 2020
Imara Inc. (IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemogl
Imara Reports First Quarter 2020 Financial Results and Business Highlights
11:00am, Thursday, 07'th May 2020
Strengthened Board of Directors and expanded leadership team with appointment of General Counsel Continued progress toward initiation of Phase 2b clinical trials of IMR-687 in.
Imara Launches ‘Real Impact’ Community Support Program to Address Unmet Needs Affecting People with Rare Genetic Blood Disorders
11:00am, Wednesday, 06'th May 2020
IMARA Inc. (IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemogl
Imara Announces Appointment of Stephen M. Migausky as General Counsel
11:00am, Monday, 04'th May 2020
Imara Inc. (IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemogl
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs May 1.) * Arcturus Therapeutics Ltd (NASDAQ: ARCT) * AstraZe
The Daily Biotech Pulse: Inovio's MERS Vaccine Data, Fast Track Designation For Erytech, FDA Approves Higher Dose Of Merck's Keytruda
12:40pm, Wednesday, 29'th Apr 2020
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs April 28.) * AstraZeneca plc (NYSE: AZN) * Arcturus Therapeu
The Daily Biotech Pulse: Pfizer Earnings, Roche's Spinal Muscular Dystrophy Treatment, Moderna COVID-19 Vaccine Update
11:36am, Tuesday, 28'th Apr 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 27) * AstraZeneca plc (NYSE: AZN) * Alnylam Pharmaceuti
Passage Bio (NASDAQ:IMRA) Downgraded by Zacks Investment Research
07:30am, Saturday, 25'th Apr 2020
Passage Bio (NASDAQ:IMRA) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Saturday, Zacks.com reports. According to Zacks, “Imara Inc
Imara Strengthens Board of Directors With Appointment of Edward R. Conner, M.D.
11:00am, Thursday, 23'rd Apr 2020
Imara Inc. (IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemogl
These 3 Biotechs Had Successful IPOs During the Coronavirus Crisis. Are They Buys?
10:39am, Thursday, 23'rd Apr 2020
These companies just raised significant cash to advance promising drug pipelines.
